Archived Monthly Oncology Tumor Boards: Updates in the Treatment of Nasopharyngeal Carcinoma
Clinical trials are continuing to investigate the role of induction chemotherapy prior to systemic therapy/radiation therapy for patients with locoregionally advanced nasopharyngeal carcinoma. New evidence regarding the addition of a PD-1 inhibitor to gemcitabine/cisplatin provides an emerging avenue of treatment for patients with recurrent or metastatic disease. It is important for clinicians to remain current on emerging treatment options for patients with nasopharyngeal carcinoma.
  • Head and Neck Cancers
  • Recorded Webcast
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation